UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

Annals of oncology, 2021-02, Vol.32 (2), p.240-249

2021

Volltextzugriff (PDF)

Patterns of genomic evolution in advanced melanoma

Nature communications, 2018-07, Vol.9 (1), p.2665-12, Article 2665

2018

Volltextzugriff (PDF)

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum

Annals of oncology, 2011-03, Vol.22 (3), p.503-514

Lønning, P.E.

2011

Volltextzugriff (PDF)

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

Oncogene, 2013-11, Vol.32 (46), p.5315-5330

2013

Volltextzugriff (PDF)

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Nature communications, 2022-01, Vol.13 (1), p.69-69, Article 69

2022

Volltextzugriff (PDF)

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Journal of investigative dermatology, 2015-07, Vol.135 (7), p.1820-1828

2015

Volltextzugriff (PDF)

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

European journal of cancer (1990), 2009-03, Vol.45 (4), p.527-535

Lønning, P.E

2009

Volltextzugriff (PDF)

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Journal of clinical oncology, 2012-03, Vol.30 (7), p.709-717

2012

Volltextzugriff (PDF)

Breast cancer prognostication and prediction: are we making progress?

Annals of oncology, 2007-09, Vol.18 (suppl-8), p.viii3-viii7

Lønning, P. E.

2007

Volltextzugriff (PDF)

Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Annals of surgery, 2023-09, Vol.278 (3), p.e540-e548

2023

Volltextzugriff (PDF)

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1580-1583

2016

Volltextzugriff (PDF)

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

International journal of cancer, 2015-07, Vol.137 (1), p.96-103

2015

Volltextzugriff (PDF)

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Volltextzugriff (PDF)

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

BMC cancer, 2012-01, Vol.12 (1), p.39-39, Article 39

2012

Volltextzugriff (PDF)

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Trends in Cancer, 2021-03, Vol.7 (3), p.181-185

Lønning, Per E

2021

Volltextzugriff (PDF)

Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer

Human mutation, 2024-01, Vol.2024 (1)

2024

Volltextzugriff (PDF)

The progenitor cell marker NG2 MPG promotes chemoresistance by activation of integrin-dependent PI3K Akt signaling

Oncogene, 2008-09, Vol.27 (39), p.5182-5194

2008

Volltextzugriff (PDF)

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Cancer & metabolism, 2019-06, Vol.7 (1), p.6-6, Article 6

2019

Volltextzugriff (PDF)

RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer

Annals of oncology, 2011-10, Vol.22 (10), p.2208-2215

2011

Volltextzugriff (PDF)

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status

The Journal of steroid biochemistry and molecular biology, 2009-10, Vol.117 (1), p.31-41

2009

Volltextzugriff (PDF)

Molecular basis for therapy resistance

Molecular oncology, 2010-06, Vol.4 (3), p.284-300

Lønning, Per E.

2010

Volltextzugriff (PDF)

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NMR in biomedicine, 2012-02, Vol.25 (2), p.369-378

2012

Volltextzugriff (PDF)

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Breast cancer research : BCR, 2018-10, Vol.20 (1), p.120-120, Article 120

2018

Volltextzugriff (PDF)

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Therapeutic Advances in Medical Oncology, 2012-05, Vol.4 (3), p.127-137

Lønning, Per E.

2012

Volltextzugriff (PDF)

1 – 25 von 435

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(420)
Mit Volltextzugriff
(374)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(299)
Humans
(286)
Life Sciences & Biomedicine
(283)
Female
(236)
Oncology
(162)
Biological And Medical Sciences
(154)
Breast Neoplasms - Drug Therapy
(154)
Medical Sciences
(138)
Middle Aged
(120)
Breast Cancer
(104)
Aged
(97)
Pharmacology. Drug Treatments
(89)
Tumors
(76)
Antineoplastic Agents
(74)
Chemotherapy
(70)
Aromatase Inhibitors
(60)
Adult
(56)
Breast Neoplasms - Metabolism
(52)
Breast Neoplasms - Genetics
(50)
Antineoplastic Agents - Therapeutic Use
(46)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

Patterns of genomic evolution in advanced melanoma

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Breast cancer prognostication and prediction: are we making progress?

Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer

The progenitor cell marker NG2 MPG promotes chemoresistance by activation of integrin-dependent PI3K Akt signaling

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status

Molecular basis for therapy resistance

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions

Suchergebnisse filtern